Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT06098651 Recruiting - Solid Tumor, Adult Clinical Trials

A Study of DCR-STAT3 in Adults With Solid Tumors

Start date: August 14, 2023
Phase: Phase 1
Study type: Interventional

This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.

NCT ID: NCT06098248 Not yet recruiting - Clinical trials for Malignant Brain Tumor

cCeLL - Ex Vivo (Confocal Fluorescence Endomicroscopy) for Intraoperative Brain Tumor Diagnosis

Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to determine if cCeLL imaging is as accurate as standard biopsy practices for brain tumor surgeries. The main question[s] it aims to answer are: - Is it as accurate as standard biopsy practices? - Can it be performed faster than standard biopsy practices? Participants will consent to having their tumor tissue assessed by both cCeLL and standard biopsy procedures. There are no additional participation requirements beyond the tumor removal surgery.

NCT ID: NCT06096974 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Start date: October 2023
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.

NCT ID: NCT06094777 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of HY-0102 in Patients With Advanced Solid Tumors

Start date: December 18, 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of HY-0102 and obtain the preliminary efficacy information of patients with advanced solid tumors.

NCT ID: NCT06094556 Recruiting - Clinical trials for Advanced Solid Tumors

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

Start date: December 25, 2023
Phase: Phase 1
Study type: Interventional

This is an open, multi-center, dose-escalation/dose-expansion/efficacy expansion phase I clinical study to evaluate the tolerability, safety, PK, and immunogenicity of SHR-1826 in patients with advanced malignant solid tumors, and to preliminatively observe its antitumor efficacy. The whole study was divided into three stages: dose increment, dose extension and therapeutic effect extension.

NCT ID: NCT06094530 Recruiting - Neoplasms Clinical Trials

18F-FAPI-RGD PET/CT in Various Tumor Types

Start date: April 10, 2023
Phase:
Study type: Observational [Patient Registry]

The clinical feasibility of 18F-FAPI-RGD PET/CT will be evaluated in 100 patients with various types of tumor, and the results will be compared with those of 18F-FDG.

NCT ID: NCT06094426 Recruiting - Solid Tumor Clinical Trials

Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

Start date: February 26, 2023
Phase: Early Phase 1
Study type: Interventional

This trial is a multicenter, single-arm, open design designed to evaluate the safety and tolerability of Autologous Tumor Infiltrating Lymphocyte Injection in the treatment of patients with advanced solid tumors, as well as pharmacokinetic profiling and efficacy. The trial consists of two phases: dose-escalation and dose-expansion.

NCT ID: NCT06093945 Completed - Malignant Tumor Clinical Trials

Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Start date: November 6, 2023
Phase: Phase 1
Study type: Interventional

The study aimed to assess the effects of omeprazole on single-dose SHR2554 in healthy subjects, exploring the pharmacokinetic changes of SHR2554 and ensuring the safety when SHR2554 is co-administered with omeprazole.

NCT ID: NCT06092580 Recruiting - Advanced Cancer Clinical Trials

Phase 1 Study of AWT020 in Advanced Cancer

Start date: September 15, 2023
Phase: Phase 1
Study type: Interventional

The aims of this clinical trial are (1) to assess the safety of AWT020 at different dose levels; (2) to determine the pharmacokinetics and pharmacodynamics of AWT020 in subjects with locally advanced or metastatic cancer who have failed standard therapy.

NCT ID: NCT06092268 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Start date: October 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in combination with other antitumor therapies in patients with advanced solid tumors.